Consequently, peptides [74] and antibodies [75] that specifically target S100A9 in the colon have shown efficacy in mouse models, reducing both colitis and CAC by inhibiting their interactions with TLR4 and RAGE. This evidence concerns the gene TLR4 and colitis.